Pfizer Raises Profit Outlook Despite Mixed Q3 Results and Market Challenges
TL;DR
Pfizer exceeded earnings estimates and raised its full-year profit guidance despite a decline in sales, driven by cost-cutting measures and a one-time charge related to a Chinese biotech licensing deal. The company also announced a significant investment in U.S. manufacturing and is involved in a bidding war for the biotech Metsera, amidst ongoing negotiations with the Trump administration over drug pricing and tariffs.
- Pfizer tops estimates, raises profit guidance even as sales fall CNBC
- Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance Yahoo Finance
- Pfizer Boosts Profit View While Chasing Obesity Startup Metsera Bloomberg.com
- Pfizer Profit Falls Amid Lower Covid-19 Drug Demand The Wall Street Journal
- Pfizer Reports Earnings on Tuesday. What to Expect. Barron's
Want the full story? Read the original reporting
Read on CNBC